Alpha 2.0
Login Register
» Authors » D Lansing Taylor

D Lansing Taylor

Explore the profile of D Lansing Taylor including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 76
Citations 1496
Followers 0
Related Specialties
Biology
Chemistry
Molecular Biology
Top 10 Co-Authors
Albert Gough
Andrew M Stern
Lawrence Vernetti
Tong Ying Shun
Mark E Schurdak
Lawrence A Vernetti
Richard DeBiasio
Mark T Miedel
Alejandro Soto-Gutierrez
Kenneth A Giuliano
Published In
Exp Biol Med (Maywood)
J Biomol Screen
Sci Rep
Assay Drug Dev Technol
Methods Mol Biol
Affiliations
Soon will be listed here.
Recent Articles
1.
A metabolic dysfunction-associated steatotic liver acinus biomimetic induces pancreatic islet dysfunction in a coupled microphysiology system
Aleman J, K R, Wiegand C, Schurdak M, Vernetti L, Gavlock D, et al.
Commun Biol . 2024 Oct; 7(1):1317. PMID: 39397070
Preclinical and clinical studies suggest that lipid-induced hepatic insulin resistance is a primary defect that predisposes to dysfunction in islets, implicating a perturbed liver-pancreas axis underlying the comorbidity of T2DM...
2.
Comparison of wild-type and high-risk PNPLA3 variants in a human biomimetic liver microphysiology system for metabolic dysfunction-associated steatotic liver disease precision therapy
Xia M, Varmazyad M, Pla-Palacin I, Gavlock D, DeBiasio R, LaRocca G, et al.
Front Cell Dev Biol . 2024 Sep; 12:1423936. PMID: 39324073
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a worldwide health epidemic with a global occurrence of approximately 30%. The pathogenesis of MASLD is a complex, multisystem disorder driven by multiple...
3.
Comparison of Wild-Type and High-risk PNPLA3 variants in a Human Biomimetic Liver Microphysiology System for Metabolic Dysfunction-associated Steatotic Liver Disease Precision Therapy
Xia M, Varmazyad M, Palacin I, Gavlock D, DeBiasio R, LaRocca G, et al.
bioRxiv . 2024 May; PMID: 38712213
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a worldwide health epidemic with a global occurrence of approximately 30%. The pathogenesis of MASLD is a complex, multisystem disorder driven by multiple...
4.
A metabolic-dysfunction associated steatotic liver acinus biomimetic induces pancreatic islet dysfunction in a coupled microphysiology system
Aleman J, Ravikumar K, Wiegand C, Schurdak M, Vernetti L, Gavlock D, et al.
bioRxiv . 2024 May; PMID: 38712135
Preclinical and clinical studies suggest that lipid-induced hepatic insulin resistance is a primary defect that predisposes to dysfunction in pancreatic islets, implicating a perturbed liver-pancreas axis underlying the comorbidity of...
5.
Polymorphisms Associated With Metabolic Dysfunction-Associated Steatotic Liver Disease Influence the Progression of End-Stage Liver Disease
Kocas-Kilicarslan Z, Cetin Z, Faccioli L, Motomura T, Amirneni S, Diaz-Aragon R, et al.
Gastro Hep Adv . 2024 Jan; 3(1):67-77. PMID: 38292457
Background And Aims: Chronic liver injury that results in cirrhosis and end-stage liver disease (ESLD) causes more than 1 million deaths annually worldwide. Although the impact of genetic factors on...
6.
Modeling mechanisms underlying differential inflammatory responses to COVID-19 in type 2 diabetes using a patient-derived microphysiological organ-on-a-chip system
Negi V, Gavlock D, Miedel M, Lee J, Shun T, Gough A, et al.
Lab Chip . 2023 Sep; 23(20):4514-4527. PMID: 37766577
: COVID-19 pandemic has caused more than 6 million deaths worldwide. Co-morbid conditions such as Type 2 Diabetes (T2D) have increased mortality in COVID-19. With limited translatability of and small...
7.
Evaluation of Human Hepatocyte Drug Metabolism Carrying High-Risk or Protection-Associated Liver Disease Genetic Variants
Faccioli L, Cetin Z, Kocas-Kilicarslan Z, Ortiz K, Sun Y, Hu Z, et al.
Int J Mol Sci . 2023 Sep; 24(17). PMID: 37686209
Metabolic-dysfunction-associated steatotic liver disease (MASLD), which affects 30 million people in the US and is anticipated to reach over 100 million by 2030, places a significant financial strain on the...
8.
The Combination of a Human Biomimetic Liver Microphysiology System with BIOLOGXsym, a Quantitative Systems Toxicology (QST) Modeling Platform for Macromolecules, Provides Mechanistic Understanding of Tocilizumab- and GGF2-Induced Liver Injury
Beaudoin J, Clemens L, Miedel M, Gough A, Zaidi F, Ramamoorthy P, et al.
Int J Mol Sci . 2023 Jun; 24(11). PMID: 37298645
Biologics address a range of unmet clinical needs, but the occurrence of biologics-induced liver injury remains a major challenge. Development of cimaglermin alfa (GGF2) was terminated due to transient elevations...
9.
Author Correction: Defective HNF4alpha-dependent gene expression as a driver of hepatocellular failure in alcoholic hepatitis
Argemi J, Latasa M, Atkinson S, Blokhin I, Massey V, Gue J, et al.
Nat Commun . 2023 Feb; 14(1):757. PMID: 36765087
No abstract available.
10.
Biofabrication of synthetic human liver tissue with advanced programmable functions
Florentino R, Morita K, Haep N, Motomura T, Diaz-Aragon R, Faccioli L, et al.
iScience . 2022 Nov; 25(12):105503. PMID: 36404924
Advances in cellular engineering, as well as gene, and cell therapy, may be used to produce human tissues with programmable genetically enhanced functions designed to model and/or treat specific diseases....